WO2002000879A3 - Methods for producing modified glycoproteins - Google Patents
Methods for producing modified glycoproteins Download PDFInfo
- Publication number
- WO2002000879A3 WO2002000879A3 PCT/US2001/020553 US0120553W WO0200879A3 WO 2002000879 A3 WO2002000879 A3 WO 2002000879A3 US 0120553 W US0120553 W US 0120553W WO 0200879 A3 WO0200879 A3 WO 0200879A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycoproteins
- human
- produce
- glycans
- fungi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01113—Mannosyl-oligosaccharide 1,2-alpha-mannosidase (3.2.1.113), i.e. alpha-1,2-mannosidase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK04025648T DK1522590T3 (en) | 2000-06-28 | 2001-06-27 | Process for Preparation of Modified Glycoproteins |
AU7684201A AU7684201A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
AT01954606T ATE309385T1 (en) | 2000-06-28 | 2001-06-27 | METHOD FOR PRODUCING MODIFIED GLYCOPROTEINS |
KR1020027017911A KR100787073B1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
CA002412701A CA2412701A1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
MXPA03000105A MXPA03000105A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins. |
AU2001276842A AU2001276842B2 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
NZ523476A NZ523476A (en) | 2000-06-28 | 2001-06-27 | Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes |
JP2002506194A JP2004501642A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
EP01954606A EP1297172B1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
DE60114830T DE60114830T2 (en) | 2000-06-28 | 2001-06-27 | PROCESS FOR PRODUCING MODIFIED GLYCOPROTEINS |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21435800P | 2000-06-28 | 2000-06-28 | |
US60/214,358 | 2000-06-28 | ||
US21563800P | 2000-06-30 | 2000-06-30 | |
US60/215,638 | 2000-06-30 | ||
US27999701P | 2001-03-30 | 2001-03-30 | |
US60/279,997 | 2001-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002000879A2 WO2002000879A2 (en) | 2002-01-03 |
WO2002000879A3 true WO2002000879A3 (en) | 2002-09-06 |
Family
ID=27395978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/020553 WO2002000879A2 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
Country Status (15)
Country | Link |
---|---|
US (13) | US7029872B2 (en) |
EP (5) | EP2322644A1 (en) |
JP (2) | JP2004501642A (en) |
KR (1) | KR100787073B1 (en) |
AT (2) | ATE440959T1 (en) |
AU (2) | AU2001276842B2 (en) |
CA (1) | CA2412701A1 (en) |
CY (1) | CY1109639T1 (en) |
DE (2) | DE60114830T2 (en) |
DK (2) | DK1297172T3 (en) |
ES (2) | ES2252261T3 (en) |
MX (1) | MXPA03000105A (en) |
NZ (1) | NZ523476A (en) |
PT (1) | PT1522590E (en) |
WO (1) | WO2002000879A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877462B2 (en) | 2000-06-28 | 2014-11-04 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US8986949B2 (en) | 2003-02-20 | 2015-03-24 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
US9574218B2 (en) | 2001-01-19 | 2017-02-21 | Phyton Holdings, Llc | Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain |
Families Citing this family (467)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
DK1137789T3 (en) | 1998-12-09 | 2010-11-08 | Phyton Holdings Llc | Process for preparing a glycosylation of human type glycosylation |
NZ518532A (en) | 1999-10-26 | 2004-02-27 | Plant Res Internat B | Transgenic plant expressing mammalian beta-1,4- galactosyltransferase |
US7198921B2 (en) * | 2000-05-17 | 2007-04-03 | Mitsubishi Pharma Corporation | Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby |
US7598055B2 (en) * | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
US20060024304A1 (en) * | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
US20060034828A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
US7863020B2 (en) * | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
US20060029604A1 (en) * | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
US20060034830A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
EP2322644A1 (en) * | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
US8697394B2 (en) | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
EP1294910B1 (en) | 2000-06-30 | 2008-11-19 | VIB vzw | Protein glycosylation modification in pichia pastoris |
WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
TWI377253B (en) | 2001-04-16 | 2012-11-21 | Martek Biosciences Corp | Product and process for transformation of thraustochytriales microorganisms |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
DK1578771T3 (en) * | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
EP2322229B1 (en) | 2001-10-10 | 2016-12-21 | Novo Nordisk A/S | Remodeling and glycoconjugation of Factor IX |
US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US20060024292A1 (en) * | 2001-12-27 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
MXPA04006357A (en) | 2001-12-27 | 2005-03-31 | Glycofi Inc | Methods to engineer mammalian-type carbohydrate structures. |
US20060034829A1 (en) * | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
US6964784B2 (en) * | 2002-03-07 | 2005-11-15 | Optigenex, Inc. | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
AU2003219418B2 (en) * | 2002-03-19 | 2008-02-28 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
NZ546945A (en) | 2002-03-19 | 2008-04-30 | Plant Res Int Bv | A plant host cell system for the expression of human GnTIII |
US7972809B2 (en) | 2002-04-26 | 2011-07-05 | National Institute Of Advanced Industrial Science & Technology | Methylotrophic yeast producing mammalian type sugar chain |
MXPA04012496A (en) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Pegylated factor vii glycoforms. |
US7252933B2 (en) * | 2002-06-26 | 2007-08-07 | Flanders Interuniversity Institute For Biotechnology | Protein glycosylation modification in methylotrophic yeast |
KR20040004089A (en) * | 2002-06-29 | 2004-01-13 | 한국생명공학연구원 | Hansenula polymorpha mutant strains with defect in outer chain biosynthesis and the production of recombinant glycoproteins using the same strains |
AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
AR042145A1 (en) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION |
RU2407796C2 (en) * | 2003-01-22 | 2010-12-27 | Гликарт Биотекнолоджи АГ | FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION |
PL222219B1 (en) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Host cells, method for producing a polypeptide, antibody, pharmaceutical composition and method for treating cancer |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
AU2012227297B2 (en) * | 2003-02-20 | 2013-11-14 | Glycofi, Inc. | Combinatorial DNA Library for Producing Modified N-Glycans in Lower Eukaryotes |
NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
WO2007022512A2 (en) * | 2005-08-19 | 2007-02-22 | Neose Technologies, Inc. | Glycopegylated factor vii and factor viia |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP1624847B1 (en) | 2003-05-09 | 2012-01-04 | BioGeneriX AG | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US9357755B2 (en) * | 2003-10-28 | 2016-06-07 | The University Of Wyoming | Production of human glycosylated proteins in silk worm |
US20070067855A1 (en) * | 2003-10-28 | 2007-03-22 | Chesapeake Perl, Inc. | Production of human glycosylated proteins in transgenic insects |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US7507573B2 (en) | 2003-11-14 | 2009-03-24 | Vib, Vzw | Modification of protein glycosylation in methylotrophic yeast |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
US7405198B2 (en) * | 2003-11-24 | 2008-07-29 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
AU2004311545B2 (en) * | 2003-12-24 | 2008-11-06 | Glycofi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
EP1765853B1 (en) | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-linked glycosylation of G-CSF peptides |
KR100604994B1 (en) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | A novel Hansenula polymorpha gene coding for ?1,6- mannosyltransferase and process for the production of recombinant glycoproteins with Hansenula polymorpha mutant strain deficient in the same gene |
WO2005090552A2 (en) * | 2004-03-17 | 2005-09-29 | Glycofi, Inc. | Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast |
WO2005089047A2 (en) * | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
CA2562772A1 (en) * | 2004-04-15 | 2005-10-27 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
JP5752582B2 (en) * | 2004-04-29 | 2015-07-22 | グライコフィ, インコーポレイテッド | Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins |
AU2005238308B8 (en) * | 2004-04-29 | 2009-10-08 | Glycofi, Inc. | Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins |
RU2006138181A (en) * | 2004-05-04 | 2008-06-10 | Ново Нордиск Хелс Кеа Аг (Ch) | O-RELATED Glycoforms of Polypeptides and a Method for Their Production |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
JP2008512355A (en) * | 2004-07-21 | 2008-04-24 | グライコフィ, インコーポレイテッド | Immunoglobulin containing predominantly GlcNAcMan5Man3GlcNAc2 glycoform |
WO2006026992A1 (en) * | 2004-09-07 | 2006-03-16 | Novozymes A/S | Altered structure of n-glycans in a fungus |
WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
US20080108557A1 (en) * | 2004-09-29 | 2008-05-08 | Novo Nordisk Healthcare A/G | Modified Proteins |
EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006071856A2 (en) * | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
ES2449195T3 (en) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Glycopegylated granulocyte colony stimulating factor |
DE602006011132D1 (en) * | 2005-03-07 | 2010-01-28 | Plant Res Int Bv | Glycoengineering in pilzen |
WO2006105426A2 (en) * | 2005-03-30 | 2006-10-05 | Neose Technologies, Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
WO2006121569A2 (en) * | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7700739B2 (en) * | 2005-06-30 | 2010-04-20 | Abbott Laboratories | IL-12/p40 binding proteins |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
CN101370525B (en) | 2005-08-19 | 2013-09-18 | Abbvie公司 | Dual variable domain immunoglobin and uses thereof |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
EP2500359A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007028144A2 (en) * | 2005-09-02 | 2007-03-08 | Glycofi, Inc | Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform |
AU2005336263A1 (en) * | 2005-09-09 | 2007-03-15 | Glycofi, Inc. | Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform |
CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
ES2542501T3 (en) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use |
KR101105718B1 (en) | 2005-10-27 | 2012-01-17 | 한국생명공학연구원 | A novel Hansenula polymorpha gene coding for dolichyl-phosphate-mannose dependent ?-1,3-mannosyltransferase and process for the production of recombinant glycoproteins with Hansenula polymorpha mutant strain deficient in the same gene |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
EP1954815B1 (en) * | 2005-11-15 | 2015-02-25 | GlycoFi, Inc. | Production of glycoproteins with reduced o-glycosylation |
CN102898519B (en) | 2005-11-30 | 2015-10-28 | Abbvie公司 | Monoclonal antibody of anti-amyloid beta protein and uses thereof |
EP2289909B1 (en) | 2005-11-30 | 2014-10-29 | AbbVie Inc. | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
US7884264B2 (en) * | 2006-01-17 | 2011-02-08 | Biolex Therapeutics, Inc. | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
US20090181041A1 (en) * | 2006-01-23 | 2009-07-16 | Jan Holgersson | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
EP2264061A1 (en) * | 2006-01-26 | 2010-12-22 | Recopharma AB | Compositions and methods for inhibiting viral adhesion |
US20110104750A1 (en) * | 2006-04-05 | 2011-05-05 | Michael Ward | Filamentous Fungi Having Reduced UDP-Galactofuranose Content |
MX2008013394A (en) * | 2006-04-21 | 2008-10-31 | Wyeth Corp | Methods for high-throughput screening of cell lines. |
JP5424871B2 (en) * | 2006-05-19 | 2014-02-26 | グライコフィ, インコーポレイテッド | Recombinant vector |
MX2008014744A (en) * | 2006-05-19 | 2009-02-10 | Glycofi Inc | Erythropoietin compositions. |
ATE516346T1 (en) * | 2006-05-24 | 2011-07-15 | Univ Provence Aix Marseille 1 | PREPARATION AND USES OF CHIMERIC GLYCOSYL TRANSFERASES WITH GENE SEQUENCES ENCODING OPTIMIZED GLYCOSYLATION ACTIVITY |
AR078117A1 (en) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE |
US20080274958A1 (en) * | 2006-07-21 | 2008-11-06 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
HUE052220T2 (en) | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin -13 binding proteins |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
CA2665644A1 (en) * | 2006-10-12 | 2008-05-29 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
WO2008073620A2 (en) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
FR2912154B1 (en) | 2007-02-02 | 2012-11-02 | Glycode | GENETICALLY MODIFIED YEASTS FOR THE PRODUCTION OF HOMOGENEOUS GLYCOPROTEINS |
DK2148691T3 (en) | 2007-02-05 | 2015-08-17 | Apellis Pharmaceuticals Inc | Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
CN101679934B (en) | 2007-03-07 | 2014-04-02 | 格利科菲公司 | Production of glycoproteins with modified fucosylation |
WO2008112192A2 (en) | 2007-03-08 | 2008-09-18 | Kalobios Pharmaceuticals, Inc. | Epha3 antibodies for the treatment of solid tumors |
MX2009010120A (en) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof. |
CA2682578C (en) | 2007-04-03 | 2015-05-26 | Oxyrane Uk Limited | Glycosylation of molecules |
NZ580030A (en) | 2007-04-03 | 2012-06-29 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
US20080256056A1 (en) * | 2007-04-10 | 2008-10-16 | Yahoo! Inc. | System for building a data structure representing a network of users and advertisers |
NZ580510A (en) | 2007-04-17 | 2011-06-30 | Stichting Dienst Landbouwkundi | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2008143878A1 (en) | 2007-05-14 | 2008-11-27 | Medimmune, Llc | Methods of reducing eosinophil levels |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
PE20090329A1 (en) * | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8637435B2 (en) * | 2007-11-16 | 2014-01-28 | Merck Sharp & Dohme Corp. | Eukaryotic cell display systems |
SG10201406572TA (en) | 2007-12-19 | 2014-11-27 | Glycofi Inc | Yeast strains for protein production |
EP2240595B2 (en) * | 2008-01-03 | 2019-07-24 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
EP2245151B1 (en) * | 2008-02-20 | 2014-12-24 | GlycoFi, Inc. | Vectors and yeast strains for protein production |
KR101582841B1 (en) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | Conjugated factor viii molecules |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
WO2009111183A1 (en) | 2008-03-03 | 2009-09-11 | Glycofi, Inc. | Surface display of recombinant proteins in lower eukaryotes |
CA2717614A1 (en) * | 2008-03-11 | 2009-09-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
PT2439212T (en) | 2008-05-02 | 2017-03-29 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
JP5890174B2 (en) | 2008-05-09 | 2016-03-22 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | Antibody against terminal glycation end product receptor (RAGE) and use thereof |
MX2010013059A (en) * | 2008-05-30 | 2010-12-20 | Glycofi Inc | Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose. |
RU2010153580A (en) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
MX2010014574A (en) | 2008-07-08 | 2011-04-27 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof. |
BRPI0915825A2 (en) | 2008-07-08 | 2015-11-03 | Abbott Lab | prostaglandin binding proteins and uses thereof |
US8067339B2 (en) | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
EP2331701B1 (en) | 2008-08-08 | 2013-03-20 | Vib Vzw | Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof |
AU2009282228A1 (en) | 2008-08-12 | 2010-02-18 | Glycofi, Inc. | Improved vectors and yeast strains for protein production: Ca2+ ATPase overexpression |
US20100120701A1 (en) | 2008-09-25 | 2010-05-13 | Glycosyn, Inc. | Compositions and Methods For Engineering Probiotic Yeast |
KR20110063650A (en) | 2008-10-01 | 2011-06-13 | 아사히 가라스 가부시키가이샤 | Host, transformant, method for producing the transformant, and method for producing heterogeneous protein containing o-glycoside type sugar chain |
US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
US20100233079A1 (en) * | 2008-12-04 | 2010-09-16 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
SG171814A1 (en) | 2008-12-19 | 2011-07-28 | Jennewein Biotechnologie Gmbh | Synthesis of fucosylated compounds |
AU2009327435A1 (en) * | 2008-12-19 | 2010-06-24 | Momenta Pharmaceuticals, Inc. | Methods related to modified glycans |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
BRPI1007371A2 (en) * | 2009-01-29 | 2018-03-27 | Abbott Lab | il-1 binding proteins |
US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
JP2012518419A (en) | 2009-02-25 | 2012-08-16 | メルク・シャープ・エンド・ドーム・コーポレイション | Metabolic manipulation of the galactose assimilation pathway in the sugar-engineered yeast Pichia pastoris |
TWI541021B (en) | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Il-17 binding proteins |
CA2753995A1 (en) | 2009-03-06 | 2010-09-10 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
US8283162B2 (en) | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
AU2010225930B2 (en) * | 2009-03-16 | 2017-01-12 | Dsm Ip Assets B.V. | Protein production in microorganisms of the phylum Labyrinthulomycota |
BRPI1009460A2 (en) | 2009-03-16 | 2016-03-01 | Cephalon Australia Pty Ltd | antibody binding domain, antibody, use of a binding domain or antibody, method for detecting the presence of cancer cells in a sample. |
EP2424894A1 (en) | 2009-04-27 | 2012-03-07 | Novartis AG | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit |
EP3275900A1 (en) | 2009-04-27 | 2018-01-31 | Novartis AG | Compositions and methods for increasing muscle growth |
US20120329709A1 (en) * | 2009-05-26 | 2012-12-27 | Brian Edward Collins | Production of glycoproteins |
WO2010138184A2 (en) * | 2009-05-27 | 2010-12-02 | Synageva Biopharma Corp. | Avian derived antibodies |
US20120121630A1 (en) * | 2009-07-24 | 2012-05-17 | Bryan Janine T | Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast |
CN105131112A (en) | 2009-08-29 | 2015-12-09 | Abbvie公司 | Therapeutic dll4 binding proteins |
WO2011028811A2 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
CN104651428A (en) | 2009-09-29 | 2015-05-27 | 根特大学 | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
PL2488554T3 (en) | 2009-10-14 | 2020-03-31 | Humanigen, Inc. | Antibodies to epha3 |
CN102666875A (en) | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
CA2776392A1 (en) | 2009-10-16 | 2011-04-21 | Merck Sharp & Dohme Corp. | Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens |
UY32979A (en) * | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
EP2494030A4 (en) | 2009-10-30 | 2013-03-27 | Merck Sharp & Dohme | Method for producing therapeutic proteins in pichia pastoris lacking dipeptidyl aminopeptidase activity |
WO2011053545A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
AU2010313608A1 (en) | 2009-10-30 | 2012-06-07 | Merck Sharp & Dohme Corp. | Methods for the production of recombinant proteins with improved secretion efficiencies |
US8420083B2 (en) * | 2009-10-31 | 2013-04-16 | Abbvie Inc. | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
EP2496257A4 (en) | 2009-11-05 | 2013-02-27 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes |
JP2013511272A (en) | 2009-11-19 | 2013-04-04 | オキシレイン ユーケー リミテッド | Yeast strain producing mammalian-like complex N-glycans |
US8722615B2 (en) | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
AU2010329955A1 (en) | 2009-12-08 | 2012-05-24 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration |
MX2012007318A (en) | 2009-12-22 | 2012-07-20 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy. |
AU2010339544B2 (en) * | 2009-12-28 | 2015-11-12 | Merial Limited | Production of hemagglutinin-neuraminidase protein in microalgae |
WO2011090730A1 (en) * | 2009-12-28 | 2011-07-28 | Martek Biosciences Corporation | Recombinant thraustochytrids that grow on xylose, and compositions, methods of making, and uses thereof |
EP2519635B1 (en) * | 2009-12-28 | 2018-11-21 | Sanofi Vaccine Technologies, S.A.S. | Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
US8715963B2 (en) * | 2010-02-24 | 2014-05-06 | Merck Sharp & Dohme Corp. | Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastoris |
KR20180044441A (en) | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | Therapeutic dll4 binding proteins |
CN102869784A (en) | 2010-04-07 | 2013-01-09 | 动量制药公司 | High mannose glycans |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
CN103096911B (en) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
CN103097523B (en) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | The innovation for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Asparaginyl-tRNA synthetase finds |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
CN105820252B (en) | 2010-05-03 | 2020-07-21 | Atyr 医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl- α -tRNA synthetases |
CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
CN103200953B (en) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
LT2571532T (en) | 2010-05-14 | 2017-08-10 | Abbvie Inc. | Il-1 binding proteins |
JP5956982B2 (en) | 2010-05-27 | 2016-07-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Method for producing antibodies having improved properties |
EP2575857B1 (en) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
WO2012013823A2 (en) * | 2010-07-30 | 2012-02-02 | Glycode | A yeast artificial chromosome carrying the mammalian glycosylation pathway |
PE20131412A1 (en) | 2010-08-03 | 2014-01-19 | Abbvie Inc | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
PT3333188T (en) | 2010-08-19 | 2022-03-28 | Zoetis Belgium S A | Anti-ngf antibodies and their use |
CN103108650A (en) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2012042387A2 (en) | 2010-09-29 | 2012-04-05 | Oxyrane Uk Limited | De-mannosylation of phosphorylated n-glycans |
WO2012042386A2 (en) | 2010-09-29 | 2012-04-05 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
JP2013543384A (en) | 2010-10-05 | 2013-12-05 | ノバルティス アーゲー | Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases |
EP2646606B1 (en) | 2010-12-01 | 2018-10-10 | Merck Sharp&Dohme Corp. | Surface-anchored fc-bait antibody display system |
WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
PE20141060A1 (en) | 2010-12-21 | 2014-09-26 | Abbvie Inc | IL-1 ALPHA AND BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USE |
US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
CN103443285B9 (en) | 2011-02-08 | 2018-04-24 | 米迪缪尼有限公司 | Antibodies that specifically bind staphylococcus aureus α toxin and methods of use |
JP2014518608A (en) | 2011-02-25 | 2014-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Yeast strains for the production of proteins with modified O-glycosylation |
WO2012125553A2 (en) | 2011-03-12 | 2012-09-20 | Momenta Pharmaceuticals, Inc. | N-acetylhexosamine-containing n-glycans in glycoprotein products |
JP2014509864A (en) | 2011-03-23 | 2014-04-24 | グリコド | Yeast recombinant cells capable of producing GDP-fucose |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
DK2707391T3 (en) | 2011-05-13 | 2018-02-05 | Gamamabs Pharma | ANTIBODIES AGAINST HER3 |
CA2834589A1 (en) | 2011-05-25 | 2012-11-29 | Merck Sharp & Dohme Corp. | Method for preparing fc-containing polypeptides having improved properties |
WO2012172521A1 (en) | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
FR2976811A1 (en) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE |
KR20140104944A (en) | 2011-06-22 | 2014-08-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Anti-axl antibodies and uses thereof |
US9409988B2 (en) | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
PL2726099T3 (en) | 2011-07-01 | 2018-12-31 | Novartis Ag | Method for treating metabolic disorders |
AU2012283039A1 (en) | 2011-07-13 | 2014-01-30 | Abbvie Inc. | Methods and compositions for treating asthma using anti-IL-13 antibodies |
EP2734537B1 (en) | 2011-07-20 | 2022-12-21 | Zepteon, Incorporated | Polypeptide separation methods |
US9371519B2 (en) * | 2011-10-03 | 2016-06-21 | National Institute Of Advanced Industrial Science And Technology | Complex type sugar chain hydrolase |
TW201323440A (en) | 2011-10-24 | 2013-06-16 | Abbvie Inc | Immunobinders directed against sclerostin |
AR088512A1 (en) | 2011-10-24 | 2014-06-18 | Abbvie Inc | ANTIBODIES DIRECTED AGAINST TNF |
BR112014009925B1 (en) | 2011-10-28 | 2022-09-20 | Teva Pharmaceuticals Australia Pty Ltd | POLYPEPTIDE BUILDERS AND THEIR USES |
KR20140091018A (en) | 2011-10-28 | 2014-07-18 | 머크 샤프 앤드 돔 코포레이션 | Engineered lower eukaryotic host strains for recombinant protein expression |
WO2013066685A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Engineered pichia strains with improved fermentation yield and n-glycosylation quality |
US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
KR101457514B1 (en) | 2011-11-21 | 2014-11-03 | 한국생명공학연구원 | Sialyltransferase of Halocynthia rorentzi and a method for synthesis of sialoglycoconjugates using it |
JP6392123B2 (en) | 2011-12-20 | 2018-09-19 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | CTP-based insulin analog for diabetes treatment |
TW201333035A (en) | 2011-12-30 | 2013-08-16 | Abbvie Inc | Dual specific binding proteins directed against IL-13 and/or IL-17 |
EP2617732A1 (en) | 2012-01-19 | 2013-07-24 | Vib Vzw | Tools and methods for expression of membrane proteins |
KR102129234B1 (en) | 2012-01-27 | 2020-07-02 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | Composition and method for the diagnosis and treatment of disease associated with neurite degeneration |
EP3311847A1 (en) | 2012-02-16 | 2018-04-25 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
BR112014022624A2 (en) | 2012-03-15 | 2017-07-11 | Oxyrane Uk Ltd | Methods and Materials for Treatment of Pompe Disease |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
CN104271816A (en) | 2012-05-11 | 2015-01-07 | 默沙东公司 | Surface anchored light chain bait antibody display system |
EP2852610B1 (en) | 2012-05-23 | 2018-07-11 | Glykos Finland Oy | Production of fucosylated glycoproteins |
US9695244B2 (en) | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
AU2013291964B2 (en) | 2012-07-18 | 2017-12-14 | Glycotope Gmbh | Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
AU2013335065B2 (en) | 2012-10-22 | 2018-10-25 | Merck Sharp & Dohme Llc | CRZ1 mutant fungal cells |
AU2013334652B2 (en) | 2012-10-23 | 2019-02-21 | Research Corporation Technologies, Inc. | Pichia pastoris strains for producing predominantly homogeneous glycan structure |
WO2014064203A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
KR20190107184A (en) | 2012-11-01 | 2019-09-18 | 애브비 인코포레이티드 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
JP6735561B2 (en) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs |
WO2014093240A1 (en) | 2012-12-10 | 2014-06-19 | The General Hospital Corporation | Bivalent il-2 fusion toxins |
WO2014090948A1 (en) | 2012-12-13 | 2014-06-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serpin spn4a and biologically active derivatives thereof for use in the treatment of cancer |
EP2931749B1 (en) | 2012-12-17 | 2019-04-24 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
EP2934589B1 (en) | 2012-12-18 | 2021-01-13 | The Rockefeller University | Glycan-modified anti-cd4 antibodies for hiv prevention and therapy |
WO2014100542A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie, Inc. | High-throughput antibody humanization |
US9458244B2 (en) | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
WO2014106015A2 (en) | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Multivalent binding protein compositions |
WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
WO2014116596A1 (en) | 2013-01-22 | 2014-07-31 | Abbvie, Inc. | Methods for optimizing domain stability of binding proteins |
MX371052B (en) | 2013-02-08 | 2020-01-14 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders. |
US9534041B2 (en) | 2013-02-12 | 2017-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that neutralize a norovirus |
ES2755181T3 (en) | 2013-02-13 | 2020-04-21 | Lab Francais Du Fractionnement | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
WO2014138188A1 (en) | 2013-03-07 | 2014-09-12 | The General Hospital Corporation | Human ctla4 mutants and use thereof |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
CA2902877A1 (en) | 2013-03-13 | 2014-10-02 | Jeffrey Boyington | Prefusion rsv f proteins and their use |
BR112015023071A2 (en) | 2013-03-14 | 2017-07-18 | Univ Indiana Res & Tech Corp | insulin-incretin conjugates |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
EP3564384A1 (en) | 2013-03-14 | 2019-11-06 | Abbott Laboratories | Hcv core lipid binding domain monoclonal antibodies |
CN105228649B (en) | 2013-03-14 | 2019-01-18 | 雅培制药有限公司 | HCV Ag-Ab combination measurement is with method and used in composition therein |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
WO2014149067A1 (en) | 2013-03-15 | 2014-09-25 | Momenta Pharmaceuticals, Inc. | Methods related to ctla4-fc fusion proteins |
BR112015023797A2 (en) | 2013-03-15 | 2017-10-24 | Abbvie Inc | dual specificity binding proteins directed against il-1b and / or il-17 |
EP3460054B1 (en) | 2013-03-15 | 2020-10-21 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
MX2015014773A (en) | 2013-04-22 | 2016-03-04 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation. |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EA033115B1 (en) | 2013-04-29 | 2019-08-30 | Тева Фармасьютикалз Острэйлиа Пти Лтд. | Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b |
EP2994163B1 (en) | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
MX2016001969A (en) | 2013-08-14 | 2016-06-02 | Novartis Ag | Methods of treating sporadic inclusion body myositis. |
KR102232348B1 (en) | 2013-09-05 | 2021-03-29 | 브이아이비 브이지더블유 | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof |
WO2015044379A1 (en) | 2013-09-27 | 2015-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A dyrk1a polypeptide for use in preventing or treating metabolic disorders |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
BR112016006999B1 (en) | 2013-10-02 | 2023-11-14 | Medimmune, Llc | ANTI-INFLUENZA NEUTRALIZING ANTIBODIES AND THEIR USES, THEIR PRODUCTION METHOD, COMPOSITION THAT COMPRISES THEM, NUCLEIC ACID AND VECTOR |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
ES2759252T3 (en) | 2013-10-31 | 2020-05-08 | Resolve Therapeutics Llc | Nuclease-albumin fusions and therapeutic methods |
ES2865196T3 (en) | 2013-11-07 | 2021-10-15 | Inst Nat Sante Rech Med | Neuregulin allosteric anti-human HER3 antibodies |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
FR3016633B1 (en) | 2014-01-17 | 2018-04-13 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | IMMUNOGLOBULIN ANTI-TOXIN CARBON |
EP3495482B1 (en) | 2014-01-21 | 2020-09-02 | Synplogen Co., Ltd. | Method for preparing dna unit composition, and method for creating concatenated dna |
TW202214691A (en) | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | Anti-egfr antibodies and antibody drug conjugates |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
US20170291939A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
US10294292B2 (en) | 2014-07-15 | 2019-05-21 | Medimmune, Llc | Neutralizing anti-influenza B antibodies and uses thereof |
US10513724B2 (en) | 2014-07-21 | 2019-12-24 | Glykos Finland Oy | Production of glycoproteins with mammalian-like N-glycans in filamentous fungi |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
UA122395C2 (en) | 2014-08-19 | 2020-11-10 | Мерк Шарп Енд Доум Корп. | ANTIBODY AGAINST TIGIT |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
WO2016050867A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune Limited | Antibodies to ticagrelor and methods of use |
CN107106656A (en) | 2014-10-29 | 2017-08-29 | 梯瓦制药澳大利亚股份有限公司 | Interferon alpha 2 b variant |
WO2016069889A1 (en) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
US11518797B2 (en) | 2014-11-11 | 2022-12-06 | Clara Foods Co. | Methods and compositions for egg white protein production |
WO2016090170A1 (en) | 2014-12-05 | 2016-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A potent anti-influenza a neuraminidase subtype n1 antibody |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
EP3091033A1 (en) | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
TWI820377B (en) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | Anti-ox40 antibodies and methods of use thereof |
JP6770533B2 (en) | 2015-05-22 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | A human monoclonal antibody fragment that inhibits both the catalytic activity of Cath-D and its binding to the LRP1 receptor. |
RU2715597C2 (en) | 2015-05-29 | 2020-03-02 | Эббви Инк. | Antibodies to cd40 and methods of use thereof |
MX2017015189A (en) | 2015-06-01 | 2018-04-13 | Medimmune Llc | Neutralizing anti-influenza binding molecules and uses thereof. |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
FR3038517B1 (en) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
AU2016290670B2 (en) | 2015-07-09 | 2020-11-05 | Universiteit Gent | Cells producing glycoproteins having altered n- and o-glycosylation patterns and methods and use thereof |
WO2017058944A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
RU2694903C1 (en) | 2015-10-12 | 2019-07-18 | АПРОДЖЕН КейАйСи ИНК. | Cd43 antibodies and use thereof for treating cancer |
JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
US11414477B2 (en) | 2016-01-27 | 2022-08-16 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
MA44236A (en) | 2016-02-17 | 2018-12-26 | Novartis Ag | ANTI-TGFBETA ANTIBODY 2 |
KR102438140B1 (en) | 2016-03-22 | 2022-08-31 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 | Humanized anti-claudin-1 antibodies and uses thereof |
LT3458479T (en) | 2016-06-08 | 2021-02-25 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
JP2019521973A (en) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | Anti-BH7-H3 antibody and antibody drug conjugate |
BR112018075651A2 (en) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anti-cd98 antibodies and drug antibody conjugates |
BR112018075653A2 (en) | 2016-06-08 | 2019-08-27 | Abbvie Inc | anti-b7-h3 antibodies and drug antibody conjugates |
JP2019521975A (en) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | Anti-EGFR antibody drug conjugate |
PE20190512A1 (en) | 2016-06-08 | 2019-04-10 | Abbvie Inc | ANTI-EGFR AND FARMACO ANTIBODY CONJUGATES |
WO2017214233A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
CA3027033A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
MX2018015272A (en) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anti-cd98 antibodies and antibody drug conjugates. |
MA45554A (en) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | OPTIMIZED BINUCLEASE FUSIONS. |
CN117717604A (en) | 2016-07-19 | 2024-03-19 | 梯瓦制药澳大利亚股份有限公司 | anti-CD 47 combination therapy |
US11186634B2 (en) | 2016-07-29 | 2021-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies targeting tumor associated macrophages and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
WO2018026969A2 (en) | 2016-08-03 | 2018-02-08 | Achaogen, Inc. | Plazomicin antibodies and methods of use |
TWI672317B (en) | 2016-08-16 | 2019-09-21 | 英屬開曼群島商岸邁生物科技有限公司 | Monovalent asymmetric tandem fab bispecific antibodies |
JP7174691B2 (en) | 2016-08-23 | 2022-11-17 | メディミューン リミテッド | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
AU2017315076B2 (en) | 2016-08-23 | 2020-10-08 | Medimmune Limited | Anti-VEGF-A antibodies and uses thereof |
US20190270821A1 (en) | 2016-09-13 | 2019-09-05 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
US11186635B2 (en) | 2016-10-25 | 2021-11-30 | Institut National De La Santé Et De La Recherché Médical (Inserm) | Monoclonal antibodies binding to the CD160 transmembrane isoform |
JP7274417B2 (en) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | 4-1BB binding protein and uses thereof |
CN110300599A (en) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | Antibody and its application method |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
JP2020510432A (en) | 2017-03-02 | 2020-04-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Antibodies with specificity for NECTIN-4 and uses thereof |
WO2018170332A1 (en) * | 2017-03-15 | 2018-09-20 | Nutech Ventures | Extracellular vesicles and methods of using |
CA3054837A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Methods for preventing and treating heart disease |
TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
EP3609922A2 (en) | 2017-04-13 | 2020-02-19 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
EP3612567A4 (en) | 2017-04-19 | 2020-11-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
WO2018219956A1 (en) | 2017-05-29 | 2018-12-06 | Gamamabs Pharma | Cancer-associated immunosuppression inhibitor |
UY37758A (en) | 2017-06-12 | 2019-01-31 | Novartis Ag | METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
US11898187B2 (en) | 2017-08-15 | 2024-02-13 | Northwestern University | Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases |
MX2020002070A (en) | 2017-08-22 | 2020-03-24 | Sanabio Llc | Soluble interferon receptors and uses thereof. |
MA49950A (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics Inc | ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
CA3091174A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
SG11202007820QA (en) | 2018-02-21 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibody dosing regimens |
WO2019169212A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
MX2020009526A (en) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof. |
US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
WO2019204346A1 (en) | 2018-04-16 | 2019-10-24 | Northwestern University | METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES |
WO2020041483A1 (en) * | 2018-08-21 | 2020-02-27 | Clara Foods Co. | Modification of protein glycosylation in microorganisms |
CN112672760A (en) | 2018-09-13 | 2021-04-16 | 德克萨斯大学体系董事会 | Novel LILRB4 antibodies and uses thereof |
EP3853251A1 (en) | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020081497A1 (en) | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
EP3877413A1 (en) | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
US20220064260A1 (en) | 2018-12-14 | 2022-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
CN113597319A (en) | 2019-01-04 | 2021-11-02 | 分解治疗有限责任公司 | Treatment of xerosis with nuclease fusion proteins |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
WO2020234399A1 (en) | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
CR20210607A (en) | 2019-06-12 | 2022-01-21 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
MX2022000374A (en) | 2019-07-11 | 2022-03-25 | Clara Foods Co | Protein compositions and consumable products thereof. |
WO2021009263A1 (en) | 2019-07-16 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for cd38 and uses thereof |
US10927360B1 (en) | 2019-08-07 | 2021-02-23 | Clara Foods Co. | Compositions comprising digestive enzymes |
US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
US20230040928A1 (en) | 2019-12-09 | 2023-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
IL294936A (en) | 2020-01-21 | 2022-09-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Utilization of plant protein homologues in culture media |
WO2021159024A1 (en) | 2020-02-05 | 2021-08-12 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021219871A2 (en) | 2020-04-30 | 2021-11-04 | Aduro Biotech Holdings, Europe B.V. | Anti-cd103 antibodies |
JP2023525053A (en) | 2020-05-12 | 2023-06-14 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | A new method to treat cutaneous T-cell lymphoma and TFH-derived lymphoma |
WO2021233834A1 (en) | 2020-05-17 | 2021-11-25 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of selecting and using the same |
JP2023528535A (en) | 2020-06-25 | 2023-07-04 | メルク・シャープ・アンド・ドーム・エルエルシー | High Affinity Antibodies Targeting Tau Phosphorylated at Serine 413 |
CA3165342A1 (en) | 2020-06-29 | 2022-01-06 | James Arthur Posada | Treatment of sjogren's syndrome with nuclease fusion proteins |
WO2022029080A1 (en) | 2020-08-03 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
WO2022034044A1 (en) | 2020-08-10 | 2022-02-17 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
JP2024504547A (en) | 2020-11-20 | 2024-02-01 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | Anti-CD25 antibody |
AR124123A1 (en) | 2020-11-20 | 2023-02-15 | Inst Nat Sante Rech Med | ANTI-CD25 ANTIBODIES |
WO2022130182A1 (en) | 2020-12-14 | 2022-06-23 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
JP2024503394A (en) | 2021-01-08 | 2024-01-25 | 北京韓美薬品有限公司 | Antibodies that specifically bind to 4-1BB and antigen-binding fragments thereof |
EP4276113A1 (en) | 2021-01-08 | 2023-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to cd47 and antigen-binding fragment thereof |
KR20230129483A (en) | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Antibodies and antigen-binding fragments that specifically bind to PD-L1 |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
EP4313317A1 (en) | 2021-03-23 | 2024-02-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of t cell-lymphomas |
WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
IL308134A (en) | 2021-06-22 | 2023-12-01 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
CN115386009B (en) * | 2022-04-26 | 2023-12-01 | 江苏靶标生物医药研究所有限公司 | Construction method and application of annexin V and angiogenesis inhibitor fusion protein |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
EP4309666A1 (en) | 2022-07-21 | 2024-01-24 | Technische Universität Dresden | M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression |
WO2024017998A1 (en) | 2022-07-21 | 2024-01-25 | Technische Universität Dresden | M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression |
WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
CN115590017B (en) * | 2022-11-04 | 2023-09-12 | 中国农业大学 | Method for improving oocyte freezing effect by reducing mitochondrial temperature |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021038A1 (en) * | 1994-12-30 | 1996-07-11 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
WO2001014522A1 (en) * | 1999-08-19 | 2001-03-01 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US513854A (en) * | 1894-01-30 | Clevis | ||
US4166329A (en) * | 1978-10-10 | 1979-09-04 | Herbig Charles A | Adjustable arch support for shoes |
US4414329A (en) | 1980-01-15 | 1983-11-08 | Phillips Petroleum Company | Biochemical conversions by yeast fermentation at high cell densities |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4617274A (en) | 1981-10-29 | 1986-10-14 | Phillips Petroleum Company | Biochemical conversions by yeast fermentation at high cell densities |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
KR850004274A (en) | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
US4655231A (en) * | 1984-01-09 | 1987-04-07 | Advanced Tobacco Products, Inc. | Snuff and preparation thereof |
US4808537A (en) | 1984-10-30 | 1989-02-28 | Phillips Petroleum Company | Methanol inducible genes obtained from pichia and methods of use |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4885242A (en) | 1984-10-30 | 1989-12-05 | Phillips Petroleum Company | Genes from pichia histidine pathway and uses thereof |
US4855231A (en) | 1984-10-30 | 1989-08-08 | Phillips Petroleum Company | Regulatory region for heterologous gene expression in yeast |
US5166329A (en) | 1985-10-25 | 1992-11-24 | Phillips Petroleum Company | DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia |
US5032516A (en) | 1985-10-25 | 1991-07-16 | Phillips Petroleum Company | Pichia pastoris alcohol oxidase II regulatory region |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US5837518A (en) * | 1986-01-31 | 1998-11-17 | Genetics Institute, Inc. | Thrombolytic proteins |
US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
US4683293A (en) | 1986-10-20 | 1987-07-28 | Phillips Petroleum Company | Purification of pichia produced lipophilic proteins |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
US5135854A (en) | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
US4816700A (en) * | 1987-12-16 | 1989-03-28 | Intel Corporation | Two-phase non-overlapping clock generator |
US5004688A (en) | 1988-04-15 | 1991-04-02 | Phillips Petroleum Company | Purification of hepatitis proteins |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5122465A (en) | 1989-06-12 | 1992-06-16 | Phillips Petroleum Company | Strains of pichia pastoris created by interlocus recombination |
US5032519A (en) | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
US5595900A (en) | 1990-02-14 | 1997-01-21 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
US5324663A (en) | 1990-02-14 | 1994-06-28 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
DE4028800A1 (en) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | GENETIC SIALYLATION OF GLYCOPROTEINS |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
US5962294A (en) | 1992-03-09 | 1999-10-05 | The Regents Of The University Of California | Compositions and methods for the identification and synthesis of sialyltransferases |
US5602003A (en) | 1992-06-29 | 1997-02-11 | University Of Georgia Research Foundation | N-acetylglucosaminyltransferase V gene |
WO1994026906A2 (en) | 1993-05-14 | 1994-11-24 | The Upjohn Company | CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE |
US5484590A (en) | 1993-09-09 | 1996-01-16 | La Jolla Cancer Research Foundation | Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family |
US6300113B1 (en) * | 1995-11-21 | 2001-10-09 | New England Biolabs Inc. | Isolation and composition of novel glycosidases |
US5683899A (en) | 1994-02-03 | 1997-11-04 | University Of Hawaii | Methods and compositions for combinatorial-based discovery of new multimeric molecules |
US6069235A (en) * | 1994-02-23 | 2000-05-30 | Monsanto Company | Method for carbohydrate engineering of glycoproteins |
US6204431B1 (en) | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
HU221001B1 (en) * | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Anti-egfr single-chain fvs, anti-egfr antibodies |
US5861293A (en) | 1994-06-13 | 1999-01-19 | Banyu Pharmaceutical Co., Ltd. | Gene encoding glycosyltransferase and its uses |
US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
ATE209644T1 (en) * | 1994-09-27 | 2001-12-15 | Yamanouchi Pharma Co Ltd | 1,2,3,4-TETRAHYDROQUINOXALINDIONE DERIVATIVES AND THEIR USE AS GLUTAMATE RECEPTOR ANTAGONISTS |
DE4439759C1 (en) * | 1994-11-07 | 1996-02-01 | Siemens Ag | Photodiode array for X=ray computer tomography |
US5849904A (en) | 1994-12-22 | 1998-12-15 | Boehringer Mannheim Gmbh | Isolated nucleic acid molecules which hybridize to polysialyl transferases |
JP2810635B2 (en) | 1995-04-03 | 1998-10-15 | 理化学研究所 | New sugar chain synthase |
JPH08336387A (en) | 1995-06-12 | 1996-12-24 | Green Cross Corp:The | Sugar chain-extended protein derived from pichia yeast and dna of the protein |
CZ89098A3 (en) * | 1995-09-29 | 1998-09-16 | Glycim Oy | SYNTHETIC POLYLACTOSAMINES CONTAINING UP TO MULTIVALENT sLEX AND METHODS OF THEIR USE |
JP3348336B2 (en) * | 1995-10-26 | 2002-11-20 | 株式会社豊田中央研究所 | Adsorption heat pump |
US5910570A (en) | 1995-11-13 | 1999-06-08 | Pharmacia & Upjohn Company | Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase |
CA2233705A1 (en) | 1996-08-02 | 1998-02-12 | The Austin Research Institute | Improved nucleic acids encoding a chimeric glycosyltransferase |
ES2235259T3 (en) | 1996-12-12 | 2005-07-01 | Kirin Beer Kabushiki Kaisha | BETA-1-4 N-ACETYLGLUCOSAMINYLTRANSPHERASE AND GEN THAT CODIFIES IT. |
US5945314A (en) | 1997-03-31 | 1999-08-31 | Abbott Laboratories | Process for synthesizing oligosaccharides |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US7029870B1 (en) * | 1997-07-03 | 2006-04-18 | Human Genome Sciences, Inc. | Gabaa receptor epsilon subunits |
WO1999012944A2 (en) * | 1997-09-05 | 1999-03-18 | Glycim Oy | SYNTHETIC DIVALENT sLex CONTAINING POLYLACTOSAMINES AND METHODS FOR USE |
JPH11103158A (en) | 1997-09-26 | 1999-04-13 | Olympus Optical Co Ltd | Flip-chip mounting to printed wiring board and mounting structure |
US7244601B2 (en) | 1997-12-15 | 2007-07-17 | National Research Council Of Canada | Fusion proteins for use in enzymatic synthesis of oligosaccharides |
JPH11221079A (en) | 1998-02-04 | 1999-08-17 | Kyowa Hakko Kogyo Co Ltd | Transglycosidase and dna encoding the same enzyme |
WO1999040208A1 (en) | 1998-02-05 | 1999-08-12 | The General Hospital Corporation | In vivo construction of dna libraries |
ES2340112T3 (en) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES. |
US6324663B1 (en) * | 1998-10-22 | 2001-11-27 | Vlsi Technology, Inc. | System and method to test internal PCI agents |
US6870565B1 (en) | 1998-11-24 | 2005-03-22 | Micron Technology, Inc. | Semiconductor imaging sensor array devices with dual-port digital readout |
DK1137789T3 (en) * | 1998-12-09 | 2010-11-08 | Phyton Holdings Llc | Process for preparing a glycosylation of human type glycosylation |
EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AU7849200A (en) | 1999-10-01 | 2001-05-10 | University Of Victoria Innovation And Development Corporation | Mannosidases and methods for using same |
AU1604401A (en) | 1999-11-19 | 2001-05-30 | Human Genome Sciences, Inc. | 18 human secreted proteins |
WO2001060860A2 (en) | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
US6410246B1 (en) * | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Highly diverse library of yeast expression vectors |
US20060024304A1 (en) | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
US20060034828A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
US20060034830A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
US8697394B2 (en) | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
US20060029604A1 (en) | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
EP1294910B1 (en) * | 2000-06-30 | 2008-11-19 | VIB vzw | Protein glycosylation modification in pichia pastoris |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
JP4655388B2 (en) | 2001-03-05 | 2011-03-23 | 富士レビオ株式会社 | Protein production method |
CA2448148A1 (en) | 2001-05-25 | 2002-12-05 | Incyte Genomics, Inc. | Carbohydrate-associated proteins |
EP2180044A1 (en) * | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
GB0120311D0 (en) * | 2001-08-21 | 2001-10-17 | Immunoporation Ltd | Treating cells |
CA2460621A1 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20060024292A1 (en) | 2001-12-27 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
MXPA04006357A (en) | 2001-12-27 | 2005-03-31 | Glycofi Inc | Methods to engineer mammalian-type carbohydrate structures. |
US20060034829A1 (en) | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
US7514253B2 (en) | 2003-05-16 | 2009-04-07 | Glycofi, Inc. | URA5 gene and methods for stable genetic integration in yeast |
WO2005018539A2 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
AU2004311545B2 (en) | 2003-12-24 | 2008-11-06 | Glycofi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
US20070154591A1 (en) * | 2003-12-30 | 2007-07-05 | Lone Andersen | Chewing gum comprising biodegradable polymers and having accelerated degradability |
WO2005090552A2 (en) | 2004-03-17 | 2005-09-29 | Glycofi, Inc. | Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast |
WO2005089047A2 (en) | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
AU2005238308B8 (en) | 2004-04-29 | 2009-10-08 | Glycofi, Inc. | Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins |
US7849651B2 (en) * | 2005-05-31 | 2010-12-14 | Kubota Matsushitadenko Exterior Works, Ltd. | Wall materials bracket and insulating wall structure |
WO2007028144A2 (en) | 2005-09-02 | 2007-03-08 | Glycofi, Inc | Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform |
EP1954815B1 (en) * | 2005-11-15 | 2015-02-25 | GlycoFi, Inc. | Production of glycoproteins with reduced o-glycosylation |
US20080274162A1 (en) * | 2007-05-04 | 2008-11-06 | Jeffrey Nessa | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository |
TW201028431A (en) * | 2008-10-31 | 2010-08-01 | Lonza Ag | Novel tools for the production of glycosylated proteins in host cells |
JP2011039027A (en) * | 2009-07-14 | 2011-02-24 | Pacific Ind Co Ltd | Metallic resin cover, method for producing the same, and door handle for vehicle |
US9439972B2 (en) * | 2012-09-10 | 2016-09-13 | Ad Lunam Labs, Inc. | Antifungal serum |
-
2001
- 2001-06-27 EP EP10011297A patent/EP2322644A1/en not_active Withdrawn
- 2001-06-27 EP EP04025648A patent/EP1522590B1/en not_active Revoked
- 2001-06-27 AU AU2001276842A patent/AU2001276842B2/en not_active Ceased
- 2001-06-27 KR KR1020027017911A patent/KR100787073B1/en not_active IP Right Cessation
- 2001-06-27 AT AT04025648T patent/ATE440959T1/en active
- 2001-06-27 DK DK01954606T patent/DK1297172T3/en active
- 2001-06-27 ES ES01954606T patent/ES2252261T3/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/US2001/020553 patent/WO2002000879A2/en active IP Right Grant
- 2001-06-27 EP EP01954606A patent/EP1297172B1/en not_active Revoked
- 2001-06-27 EP EP10012383.5A patent/EP2339013B1/en not_active Expired - Lifetime
- 2001-06-27 JP JP2002506194A patent/JP2004501642A/en active Pending
- 2001-06-27 DE DE60114830T patent/DE60114830T2/en not_active Revoked
- 2001-06-27 MX MXPA03000105A patent/MXPA03000105A/en active IP Right Grant
- 2001-06-27 ES ES04025648T patent/ES2330330T3/en not_active Expired - Lifetime
- 2001-06-27 US US09/892,591 patent/US7029872B2/en not_active Expired - Fee Related
- 2001-06-27 AT AT01954606T patent/ATE309385T1/en not_active IP Right Cessation
- 2001-06-27 DE DE60139720T patent/DE60139720D1/en not_active Expired - Lifetime
- 2001-06-27 CA CA002412701A patent/CA2412701A1/en not_active Abandoned
- 2001-06-27 NZ NZ523476A patent/NZ523476A/en not_active IP Right Cessation
- 2001-06-27 AU AU7684201A patent/AU7684201A/en active Pending
- 2001-06-27 DK DK04025648T patent/DK1522590T3/en active
- 2001-06-27 PT PT04025648T patent/PT1522590E/en unknown
- 2001-06-27 EP EP09004758A patent/EP2119793A1/en not_active Withdrawn
-
2005
- 2005-09-30 US US11/240,432 patent/US7326681B2/en not_active Expired - Fee Related
- 2005-10-11 US US11/249,061 patent/US7923430B2/en not_active Expired - Fee Related
- 2005-11-01 US US11/265,444 patent/US20070178551A1/en not_active Abandoned
- 2005-11-10 US US11/271,235 patent/US7629163B2/en not_active Expired - Fee Related
- 2005-11-10 US US11/271,217 patent/US20070105127A1/en not_active Abandoned
-
2007
- 2007-10-30 US US11/981,408 patent/US8211691B2/en not_active Expired - Fee Related
-
2009
- 2009-08-27 US US12/549,062 patent/US7981660B2/en not_active Expired - Fee Related
- 2009-11-25 CY CY20091101214T patent/CY1109639T1/en unknown
-
2010
- 2010-10-11 US US12/901,843 patent/US20110020870A1/en not_active Abandoned
-
2011
- 2011-03-17 JP JP2011059620A patent/JP2011167194A/en active Pending
-
2012
- 2012-05-01 US US13/461,111 patent/US20120322100A1/en not_active Abandoned
-
2013
- 2013-07-03 US US13/934,551 patent/US20130295604A1/en not_active Abandoned
-
2014
- 2014-05-07 US US14/271,475 patent/US20140234902A1/en not_active Abandoned
-
2015
- 2015-10-30 US US14/927,519 patent/US20160068880A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021038A1 (en) * | 1994-12-30 | 1996-07-11 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
WO2001014522A1 (en) * | 1999-08-19 | 2001-03-01 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
EP1211310A1 (en) * | 1999-08-19 | 2002-06-05 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
Non-Patent Citations (6)
Title |
---|
CHIBA YASUNORI ET AL: "Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26298 - 26304, XP002202331, ISSN: 0021-9258 * |
KALSNER INGE ET AL: "Insertion into Aspergillus nidulans of functional UDP-GlcNAc: alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyl-transferase I, the enzyme catalysing the first committed step from oligomannose to hybrid and complex N-glycans.", GLYCOCONJUGATE JOURNAL, vol. 12, no. 3, 1995, pages 360 - 370, XP001073956, ISSN: 0282-0080 * |
MARTINET W ET AL: "MODIFICATION OF THE PROTEIN GLYCOSYLATION PATHWAY IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS", BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 20, no. 12, December 1998 (1998-12-01), pages 1171 - 1177, XP001006335, ISSN: 0141-5492 * |
NAKAYAMA K-I ET AL: "OCH1 ENCODES A NOVEL MEMBRANE BOUND MANNOSYLTRANSFERASE OUTER CHAIN ELONGATION OF ASPARAGINE-LINKED OLIGOSACCHARIDES", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 11, no. 7, 1992, pages 2511 - 2519, XP002202332, ISSN: 0261-4189 * |
NIKAWA J-I ET AL: "Structural and functional conservation of human and yeast HCP1 genes which can suppress the growth defect of the Saccharomyces cerevisiae ire15 mutant", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 171, no. 1, 24 May 1996 (1996-05-24), pages 107 - 111, XP004042777, ISSN: 0378-1119 * |
WIGGINS CHRISTINE A R ET AL: "Activity of the yeast MNN1 alpha-1,3-mannosyltransferase requires a motif conserved in many other families of glycosyltransferases.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 14, 7 July 1998 (1998-07-07), July 7, 1998, pages 7945 - 7950, XP002202333, ISSN: 0027-8424 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877462B2 (en) | 2000-06-28 | 2014-11-04 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US8883483B2 (en) | 2000-06-28 | 2014-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US9574218B2 (en) | 2001-01-19 | 2017-02-21 | Phyton Holdings, Llc | Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain |
US8986949B2 (en) | 2003-02-20 | 2015-03-24 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002000879A3 (en) | Methods for producing modified glycoproteins | |
WO2007087420A8 (en) | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof | |
WO2004074458A3 (en) | N-acetylglucosaminyltransferase iii expression in lower eukaryotes | |
MXPA04006357A (en) | Methods to engineer mammalian-type carbohydrate structures. | |
Wu et al. | High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol | |
WO1998006835A3 (en) | Modifying insect cell gylcosylation pathways with baculovirus expression vectors | |
WO2003100013A3 (en) | NON-REVERTIBLE β-OXIDATION BLOCKED CANDIDA TROPICALIS | |
EP2196540A3 (en) | Combinatorial DNA library for producing modified N-Glycans in lower eukaryotes | |
WO1999067398A3 (en) | Overexpression of phytase genes in yeast systems | |
DE69837604D1 (en) | Expression heterologer proteine | |
MX2008000200A (en) | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof. | |
CA2490268A1 (en) | Protein glycosylation modification in pichia pastoris | |
EP0897010A3 (en) | Modified phytases | |
AU2003210405A1 (en) | Inbred embryonic stem-cell derived mice | |
WO1999060102A3 (en) | Improved in vivo production of cephalosporins | |
MX9606476A (en) | The cytoplasmic inhibition of gene expression. | |
WO2006096050A3 (en) | Glycoengineering in mushrooms | |
US20120029174A1 (en) | Methods for producing substantially homogeneous hybrid or complex n-glycans in methylotrophic yeasts | |
WO2021195464A3 (en) | Modified mammalian cells having reduced host cell proteins | |
CN204788079U (en) | Net adds muscle formula shell structure | |
Lee et al. | Expression of Escherichia coli AppA2 phytase in four yeast systems | |
CA2230975A1 (en) | Wheat aleurone promoter | |
WO2021231488A3 (en) | D-allulose 3-epimerases for bioconversion of d-fructose to d-allulose | |
WO2004011670A3 (en) | Methods and compositions for nad(p)(h) oxidases | |
CN1918297B (en) | Hansenula polymorpha gene coding for alpha 1,6-mannosyltransferase and process for the production of recombinant glycoproteins with hansenula polymorpha mutant strain deficient in the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412701 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001276842 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 506194 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027017911 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523476 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000105 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001954606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001954606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017911 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 523476 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523476 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001954606 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001276842 Country of ref document: AU |